Global Paroxetine Hydrochloride Tablet Market Likely to Boost Future Growth by 2028

The paroxetine hydrochloride tablet market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Paroxetine Hydrochloride is an antidepressant that is used in the treatment of MDD, panic attacks, OCD, PTSD, SAD (social phobia), and a severe type of premenstrual syndrome. Mood, sleep, appetite, and energy levels are all improved with this medicine. It is been also used to reduce fear, anxiety, unpleasant thoughts, and panic attacks. This medicine lessens the desire to conduct repetitive chores that are inconvenient in everyday life. It is a selective serotonin reuptake inhibitor (SSRI) and works by assisting in the restoration of a natural substance (serotonin) equilibrium in the brain. The rising prevalence of depression and anxiety are the major factors driving the growth of the global paroxetine hydrochloride tablet market.

Market Coverage
The market number available for – 2021-2028
Base year- 2021
Forecast period- 2022-2028
Segment Covered-
By Application
Regions Covered-
North America
Europe
Asia-Pacific
Rest of the World

Competitive Landscape-
Pfizer Inc., Cipla Inc., Teva Pharmaceutical Industries Ltd., Mylan NV, Aurobindo Pharma Ltd., Lupin Pharmaceuticals Inc., and Sun Pharmaceutical Industries Ltd., among others.

Key questions addressed by the report
What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How has COVID-19 impacted the market?
Deviation from the pre-COVID-19 forecast
Most affected region and segment
Who is the leader in the market?
How players are addressing challenges to sustain growth?
Where is the investment opportunity?